Cargando…
Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
The emerging debate between primary tumor location and clinical outcome of bevacizumab treated metastatic colorectal cancer (mCRC) continues. The aim of the present study is to investigate the association between the primary tumor location and clinical outcome of 115 mCRC patients receiving bevacizu...
Autores principales: | You, Xia-Hong, Wen, Can, Xia, Zi-Jin, Sun, Fan, Li, Yao, Wang, Wei, Fang, Zhou, Chen, Qing-Gen, Zhang, Lei, Jiang, Yu-Huang, Wang, Xiao-Zhong, Ying, Hou-Qun, Zong, Zhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702298/ https://www.ncbi.nlm.nih.gov/pubmed/31475100 http://dx.doi.org/10.3389/fonc.2019.00723 |
Ejemplares similares
-
Prognostic Impact of Tumor Status, Nodal Status and Tumor Sidedness in Metastatic Colon Cancer
por: Mukkamalla, Shiva Kumar R, et al.
Publicado: (2020) -
The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
por: Kim, Seung Tae, et al.
Publicado: (2018) -
Bevacizumab in metastatic colorectal cancer in a real-life setting – toxicity profile, survival outcomes, and impact of tumor sidedness
por: Chibani, Hind, et al.
Publicado: (2022) -
The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019) -
Tim3 and PD-1 as a therapeutic and prognostic targets in colorectal cancer: Relationship with sidedness, clinicopathological parameters, and survival
por: Mokhtari, Zahra, et al.
Publicado: (2023)